How should anxiety refractory to bupropion (Wellbutrin) 300 mg daily and hydroxyzine be managed?

Management of Anxiety Refractory to Wellbutrin 300mg and Hydroxyzine

Switch from bupropion to an SSRI (such as escitalopram, sertraline, or paroxetine) or the SNRI venlafaxine, as these are the guideline-recommended first-line pharmacologic treatments for anxiety disorders, while bupropion is not FDA-approved for anxiety and can potentially worsen anxiety symptoms. 1, 2

Why Bupropion is Problematic for Anxiety

• Bupropion (Wellbutrin) is FDA-approved only for major depressive disorder and seasonal affective disorder, not for any anxiety disorder. 2

• The medication's stimulating properties through norepinephrine and dopamine reuptake inhibition can provoke or worsen anxiety, particularly at higher doses like 300mg. 3 Common adverse effects include agitation, anxiety, insomnia, and palpitations—all of which can exacerbate anxiety symptoms. 2

• While some limited data suggest bupropion may have comparable anxiolytic effects to SSRIs in mild anxiety comorbid with depression, the evidence remains inconclusive and is not robust enough to support its use as an anxiety treatment. 4, 3

• A 2025 review explicitly states that bupropion's role in anxiety remains debated, with its stimulating properties capable of provoking anxiety. 3

Guideline-Recommended First-Line Treatment

SSRIs are the recommended first-line pharmacotherapy for anxiety disorders, with weak recommendation strength but consistent guideline support. 1

• Specific SSRIs to consider include escitalopram, sertraline, paroxetine, or fluvoxamine for various anxiety disorders. 1

• Venlafaxine (an SNRI) is also suggested as first-line treatment with equivalent recommendation strength to SSRIs. 1

Hydroxyzine Considerations

Hydroxyzine has demonstrated efficacy superior to placebo for generalized anxiety disorder, but the evidence quality is limited by high risk of bias and small sample sizes. 5, 6

• In controlled trials, hydroxyzine showed greater improvement on the Hamilton Anxiety Scale compared to placebo (10.75 vs 7.23 points). 5

• However, a Cochrane review concluded that due to high risk of bias and limited data, hydroxyzine cannot be recommended as a reliable first-line treatment for GAD. 6

• The primary side effect is sedation/drowsiness, which may limit tolerability. 5, 6

Recommended Treatment Algorithm

Step 1: Discontinue or Taper Bupropion

• When discontinuing Wellbutrin XL 300mg, taper to 150mg once daily before complete discontinuation to minimize withdrawal effects. 2
• Allow at least 14 days washout if planning to start an MAOI (though this is unlikely in anxiety treatment). 2

Step 2: Initiate SSRI or SNRI

• Start with an SSRI such as escitalopram 10mg daily or sertraline 50mg daily, which can be titrated based on response. 1
• Alternatively, venlafaxine can be initiated if SSRIs are contraindicated or not preferred. 1
• Continue hydroxyzine during the transition if it provides any symptomatic relief, as SSRIs typically require 2-4 weeks for anxiolytic effects. 6

Step 3: Consider Adjunctive Strategies if Partial Response

• If anxiety remains refractory to adequate SSRI/SNRI monotherapy (8-12 weeks at therapeutic doses), consider cognitive behavioral therapy specifically designed for anxiety disorders. 1
• Individual CBT based on established models (Clark and Wells or Heimberg) is recommended over group therapy. 1

Step 4: Alternative Augmentation (If Still Refractory)

• For treatment-resistant cases, adjunctive aripiprazole at low doses (2.5-10mg daily) has shown benefit in depression refractory to other antidepressants, though data specific to bupropion-refractory anxiety is limited. 7
• This strategy showed rapid improvement in depressive symptoms with good tolerability in case reports. 7

Critical Pitfalls to Avoid

• Do not combine bupropion with SSRIs/SNRIs without clear indication for depression, as this increases side effect burden without established benefit for primary anxiety disorders. 8

• Monitor closely for activation syndrome, agitation, or suicidal ideation when initiating any antidepressant, particularly in younger adults. 2

• Avoid long-term benzodiazepine use as a primary strategy, though short-term bridging during SSRI initiation may be appropriate. 6

• Do not assume hydroxyzine failure means all pharmacotherapy will fail—the evidence base for hydroxyzine is weak compared to SSRIs/SNRIs. 6